Press releases
- BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- BioLineRx to Report First Quarter 2024 Results on May 28, 2024
- BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
- BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
- BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
- BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
- BioLineRx Announces $6 Million Registered Direct Offering
- BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
- BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
- BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
More ▼
Key statistics
As of last trade BioLine RX Ltd (YP2A:STU) traded at 0.545, 6.86% above its 52-week low of 0.51, set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.540 |
---|---|
High | 0.545 |
Low | 0.540 |
Bid | 0.540 |
Offer | 0.590 |
Previous close | 0.55 |
Average volume | 0.00 |
---|---|
Shares outstanding | 79.94m |
Free float | 12.37m |
P/E (TTM) | -- |
Market cap | 52.62m USD |
EPS (TTM) | -0.9509 USD |
Data delayed at least 15 minutes, as of May 23 2024.
More ▼